ライフサイエンスコーパス: BP

1 BP measurements were taken during six antenatal visits.

2 BP was measured 3 times following a standardized protoco

3 BP was measured by trained staff using standardized meth

4 BP was monitored by telemetry.

5 BP, serum lipids, body mass index, and smoking were asse

6 l (n=19 770; 90%) or hypotensive (n=274; 1%) BP responses (32% versus 21% versus 23%, respectively; P

7 Five (E2, DES, DPN, BPAF, Coum, 1-BP) of 16 compounds tested by reporter assay had estroge

8 ging from 23,100 +/- 3300 to 29,400 +/- 2300 BP, and three AMS radiocarbon dates from charcoal sample

9 regulation of the translation repressor, 4E-BP (eukaryotic translation initiation factor 4E-binding

10 We show that 4E-BP determines Drosophila lifespan in the context of temp

11 ation factor 4E (eIF4E)-binding proteins (4E-BPs).

12 BP] = 1.3 x 10-3) and LOAD (P = 6.22 x 10-6; BP = 4.1 x 10-3).

13 a BP) provides a key time marker for the LGM in the New Ze

14 ps of participants in both SPRINT and ACCORD-BP who had lower versus higher ARRs in CVD events/deaths

15 In ACCORD-BP, participants in the highest subgroup of predicted be

16 e CVD risk reduction, but the overall ACCORD-BP participant sample was skewed towards participants wi

17 months 3 and 4 of the trial (time to achieve BP goals).

18 There was no heterogeneity across BP molecules and no trend according to cumulative dose,

19 Through this procedure, afferent BP-related neural profiles (BPnPs) were derived from the

20 duction of cytochrome P450 eicosanoids alter BP.

21 Ambulatory BP data at 12 months were available from 4 trials (1,478

22 differences between clinic BP and ambulatory BP (ABP) in a community sample of employed adults in the

23 hanges in mean clinic BP or awake ambulatory BP.

24 pertension was defined as daytime ambulatory BP of at least 135/85 mm Hg and was further divided into

25 e on BP readings, and explore how ambulatory BP data from the SPRINT trial may inform this discussion

26 ment was adjusted on the basis of ambulatory BP), we simultaneously monitored BP and physical activit

27 ive renal plasma flow (para-aminohippurate), BP, and hemodynamic responses to an infusion of angioten

28 The association among BP reduction, ICH expansion, and outcome was investigate

29 >300 mg/24 h despite ramipril at 10 mg/d and BP<140/90 mmHg were treated for four 8-week periods with

30 the associations between changes in DWS and BP when participants experienced changing sodium levels

31 among the three techniques regarding NP and BP penetration into rice plant roots and spICP-MS showed

32 enes, ROS levels, CB chemosensory reflex and BP, and also stabilized breathing.

33 are also involved in the control of RMR and BP, but whether this regulation overlaps with leptin's a

34 he impact of polygenic risk of MDD, SCZ, and BP on subcortical brain volumes and white matter (WM) mi

35 lized particles differed between the NPs and BPs with the NPs showing a distribution with smaller par

36 For this latter approach, BP thresholds were identified only for SBP because clini

37 y splicing regulatory protein (KSRP), an ARE-BP, is robustly up-regulated in human lung cancer.

38 NP, regulate fluid homeostasis and arterial BP through renal actions involving increased GFR and vas

39 derive individualized mean awake and asleep BP.

40 Compared to bare BPs, BPs with TiL4 modification (TiL4 @BPs) can efficien

41 r BP than littermate controls, whereas basal BP was unaltered in Cdh5-CreERT2 Nox2KO mice (in which N

42 based measurement of BP for achieving better BP control or for preventing adverse clinical outcomes t

43 rs10995 G-allele was associated with better BP response to hydrochlorothiazide versus noncarriers (D

44 tudinal race-stratified associations between BP and cardiovascular outcomes.

45 We examined the relationship between BP and cerebral ischemia (relative drop in cerebral satu

46 The relationship between BP and downstream ischemia during hemodialysis has not b

47 The transformation between BPs, where crystal features arise in the submicron regim

48 A bipolar (BP) nanosecond electric pulse (nsEP) exposure generates

49 Compared to bare BPs, BPs with TiL4 modification (TiL4 @BPs) can efficiently e

50 (PVP) waveform and calibrate it to brachial BP levels estimated with population average methods.

51 ble for left ventricular mass, unaffected by BP and total body overhydration.

52 44,200-42,350 cal BP, and 54,400-46,050 cal BP (all at the 95.4% confidence level).

53 s of 38,650-36,750 cal BP, 44,200-42,350 cal BP, and 54,400-46,050 cal BP (all at the 95.4% confidenc

54 me layer, yielding ages of 38,650-36,750 cal BP, 44,200-42,350 cal BP, and 54,400-46,050 cal BP (all

55 /50) and peripheral blood mononuclear cells (BP case/control: 193/593).

56 hod was developed to further advance central BP measurement.

57 y the 10S (+)-trans-BP-N (2)-dG, 10R (+)-cis-BP-N (2)-dG, and 10S ( - )-cis-BP-N (2)-dG.

58 , 10R (+)-cis-BP-N (2)-dG, and 10S ( - )-cis-BP-N (2)-dG.

59 ion of systematic differences between clinic BP and ambulatory BP (ABP) in a community sample of empl

60 ic BP, independent of changes in mean clinic BP or awake ambulatory BP.

61 39 million US adults with nonelevated clinic BP, no history of overt cardiovascular disease, and no u

62 nearly 1 in 8 adults with nonelevated clinic BP-and suggests that millions of US adults may be miscla

63 s having hypertension based on out-of-clinic BP.

64 se hemodynamic changes and maintain constant BP in salt resistance, renal and peripheral vascular res

65 With CVR = BP/CBF, Slope-CVRICA , Slope-CVRVA and Slope-CVRiMCA wer

66 Over the past several decades, BP has declined and hypertension control has improved.

67 -specific American Heart Association-defined BP categories.

68 We determined BP thresholds for ambulatory hypertension in a US popula

69 Diastolic BP decreased by 12.2 mm Hg (95% CI, 11.2-13.2 mm Hg) in

70 05 and increased slightly to 2014, diastolic BP z-score decreased slightly from 1999 to 2004 and then

71 h BP (P<10(-320)) for systolic and diastolic BP and CVD events regardless of the underlying BP geneti

72 re the differences in systolic and diastolic BP changes from baseline to the end of follow-up of pati

73 ional associations of systolic and diastolic BP with blood-derived genome-wide DNA methylation measur

74 dividual variation in systolic and diastolic BP, respectively.

75 -0.744) for clinic systolic BP and diastolic BP.

76 elta systolic BP P=3x10(-4), Delta diastolic BP P=5x10(-5)).

77 ncarriers (Delta systolic BP/Delta diastolic BP: -12.3/-8.2 versus -6.8/-3.5 mm Hg, respectively, Del

78 and from the 92.9th to 98.9th for diastolic BP in the reconstructed population.

79 .06) and a 0.63-mm Hg decrement in diastolic BP (95% CI: -1.35, 0.09), controlling for sex, age, site

80 ation analysis with systolic BP or diastolic BP or pulse pressure.

81 ean age was 48 years, and mean SBP/diastolic BP was 135/86 mm Hg.

82 reds of genes connected to bipolar disorder (BP).

83 The suspected endocrine disruptor BP-3 has been detected in the air and settled dust of ho

84 ntify novel biomarkers of thiazide diuretics BP response.

85 ically relevant xenogeneic biomaterial (i.e. BP) and further validates a rapid, high-throughput metho

86 recovery with SCX was above 86.6% for eight BPs.

87 sure (BP) in the clinic setting and elevated BP assessed by ambulatory monitoring, is associated with

88 inical outcomes that are related to elevated BP?

89 of alpha-Klotho in association with enhanced BP, decreased expression of angiotensin converting enzym

90 and 1 independent variant at an established BP locus.

91 0-60 points), improved, with the median FACT-BP score of 28 (points) before treatment increasing to a

92 Assessment of Cancer Therapy-Bone Pain (FACT-BP) scores (scale, 0-60 points), improved, with the medi

93 e genome-wide significant (P<5x10(-)(8)) for BP, of which 4 are new BP loci: rs9678851 (missense, SLC

94 Urine was analyzed for BP-3, a metabolite (BP-1), and six other UV filters.

95 may be a promising therapeutic approach for BP.

96 The appropriate target for BP in patients with CKD and hypertension remains uncerta

97 urs frequently, is not easily predicted from BP, and may be clinically significant.

98 nriched Gene Ontology Biological Process (GO BP) terms, actin cytoskeleton organization, actin filame

99 6.8%) and 39.0% (95% CI: 36.4% to 41.6%) had BP above the treatment goal according to the 2017 ACC/AH

100 rcumference; overweight and obesity; height; BP; and longitudinal growth trajectories.

101 th intensive (systolic BP target <120 mm Hg) BP treatment and data from the National Health and Nutri

102 dration (bioimpedance spectroscopy), 24-hour BP, and left ventricular mass (cardiac magnetic resonanc

103 Overall, however, BP poorly predicted downstream ischemia.

104 three structures, the bulky and hydrophobic BP pyrenyl residue is entirely solvent-exposed in the ma

105 mpared with those with normal or hypotensive BP responses but are not more likely to have false-posit

106 ears, disparities in the prevalence of ideal BP were observed, with the prevalence being lower among

107 ce and control littermates did not differ in BP, GFR, or natriuresis under baseline conditions.

108 he diagnostic relevance of anti-BP180 IgE in BP, and to correlate anti-BP180 IgE with disease activit

109 rmine the rate of anti-BP180-reactive IgE in BP, to evaluate the diagnostic relevance of anti-BP180 I

110 n salt sensitivity, promoting an increase in BP in these individuals.

111 ay alter the expression of genes involved in BP regulation and explain part of the missing heritabili

112 evels, but the cell-specific role of Nox2 in BP regulation is unknown.

113 ify distinct cell-specific roles for Nox2 in BP regulation.

114 lable BP genetic database (BP_GD), including BP related genes, drugs, pathways, diseases and supporti

115 ensive medications to achieve individualised BP goals is recommended.

116 rthermore, IgE autoantibodies fail to induce BP in eosinophil-deficient mice, confirming that eosinop

117 ation at cg08035323 (TAF1B-YWHAQ) influences BP, while BP influences methylation at cg00533891 (ZMIZ1

118 Intensive BP lowering was associated with a 29% reduction in MACE

119 Intensive BP-lowering treatment showed a (non-significant) trend f

120 on that should be tolerated during intensive BP lowering and its association with risk of ESRD are un

121 acute eGFR declines >/=20% during intensive BP lowering identified a subset of patients at higher ri

122 ith acute ICH randomised to either intensive BP-lowering or standard BP-lowering treatment protocols.

123 rtension but no diabetes mellitus, intensive BP lowering (target systolic BP <120 mm Hg) compared wit

124 vascular disease (CVD) benefits of intensive BP lowering in this population.

125 The effect of intensive BP lowering on significant haematoma expansion at 24 hou

126 In older hypertensive patients, intensive BP control (systolic BP <140 mm Hg) decreased MACE, incl

127 declines in kidney function in the intensive BP lowering arm of two trials in CKD associated with hig

128 Trial): 4086 randomly assigned to intensive BP lowering (target SBP <120 mm Hg) and 4078 assigned to

129 lar between patients randomised to intensive BP-lowering treatment and standard BP-lowering treatment

130 ed trials (RCTs) to assess whether intensive BP lowering in patients with acute ICH is safe and effec

131 her ARRs in CVD events/deaths with intensive BP treatment, and participants who had lower versus high

132 hird drought phase centred on ca. 1.8-1.1 ka BP led to markedly reduced C accumulation and potentiall

133 ered in Amazonia (peat initiation ca. 8.9 ka BP), and developed in three stages: (i) peat initiated i

134 and (iii) raised peat dome (since ca. 3.9 ka BP).

135 markably, the widespread cooling at 8.2 kcal BP is not seen very well as a temperature change, but as

136 itable (h(2) > 30%) and independent of known BP genetic variants, explaining an additional 1.4% and 2

137 discovered that the degradation of few-layer BP flakes of <10 nm can be suppressed for months by usin

138 Compared with males, females have lower BP before age 60, blunted hypertensive response to angio

139 nt in myeloid cells) had significantly lower BP than littermate controls, whereas basal BP was unalte

140 argeting SBP less than 120 mm Hg, that lower BP targets are beneficial for high-risk patients.

141 effectiveness of BP self-monitoring to lower BP and control hypertension.

142 y of a clean cookstove intervention to lower BP during pregnancy.

143 onitoring alone is not associated with lower BP or better control, but in conjunction with co-interve

144 are this extended binding interface with m4E-BPs, with significant implications on the understanding

145 Mean BP subsequently increased further in SS rats and remaine

146 d patients and their providers self-measured BP may be a helpful adjunct to routine office care.

147 andomized controlled trials of self-measured BP versus usual care at 6 but not 12 months, and for sel

148 Urine was analyzed for BP-3, a metabolite (BP-1), and six other UV filters.

149 ambulatory BP), we simultaneously monitored BP and physical activity (wrist actigraphy) for 48 hours

150 Black phosphorus nanosheets (BPs) show great potential for various applications inclu

151 eurons, regenerated retinal bipolar neurons (BPs), although reduced in numbers, reconnected to undama

152 nt (P<5x10(-)(8)) for BP, of which 4 are new BP loci: rs9678851 (missense, SLC4A1AP), rs7437940 (AFAP

153 e identified a potentially independent novel BP-associated SNV, rs3416322 (missense, SYNPO2L) at a kn

154 ugh regenerated BPs were reduced in numbers, BP dendritic spreads, dendritic tree morphologies, and c

155 s previously been reported in 22% to 100% of BP serum samples, and the pathogenic relevance of anti-B

156 out activation in the presence or absence of BP autoantibodies, brefeldin A, diphenyleneiodonium, DNa

157 Analyses of BP changes during follow-up revealed 27% reduction in th

158 analyzed the strong anisotropic behavior of BP by scanning Raman microscopy providing an accurate me

159 ansition probabilities between categories of BP using Markov modeling of cross-sectional data from th

160 posed to air at an elevated concentration of BP-3 for 32 days; the final air concentration was 4.4 mu

161 quids, paving the way for the development of BP-based technologies.

162 ed to better understand the effectiveness of BP self-monitoring to lower BP and control hypertension.

163 prediction models to tailor the intensity of BP control based on the projected risk and benefit for e

164 Despite similar levels of BP among wild-type (MYH9(+/+) ) mice and mice heterozygo

165 tested using pharmacological manipulation of BP via the Modified Oxford technique at rest and during

166 n is superior to office-based measurement of BP for achieving better BP control or for preventing adv

167 ally, an accurate and standardised method of BP measurement in the outpatient setting is essential to

168 In an ex vivo human model of BP, normal human skin cryosections were incubated with p

169 nd large third-order optical nonlinearity of BP.

170 urate method for monitoring the oxidation of BP via statistical Raman spectroscopy.

171 e role of eosinophils in the pathogenesis of BP with a specific focus on blister formation and to def

172 lso found that the phonon mean-free-paths of BP are rather long (up to 1 microm) in the through-plane

173 y demonstrate the outstanding performance of BP as a sensing channel for FET biosensor applications.

174 activation with IL-5 and in the presence of BP autoantibodies, eosinophils induced separation along

175 e to BP blister formation in the presence of BP autoantibodies.

176 tihypertensive medication, and prevalence of BP above the treatment goal among U.S. adults using crit

177 patients in the upper and lower quartile of BP response to TD from the Pharmacogenomic Evaluation of

178 better understanding of the current stage of BP genetic research and assist further studies in the fi

179 dings may not only guide the applications of BPs, but also propose an efficient strategy to further i

180 y to further improve the biocompatibility of BPs.

181 t work might lead to substantial benefits on BP control at the population level.

182 mixed methods to model the effects of DWS on BP and assessed the associations between changes in DWS

183 ose levels are attenuated and its effects on BP and HR are abolished.

184 chosocial work factors from the ERI model on BP control in treated workers.

185 luate the effect of measurement technique on BP readings, and explore how ambulatory BP data from the

186 tructure, and polygenic risk for MDD, SCZ or BP.

187 anium dioxide NPs and larger bulk particles (BPs) in rice plant (Oryza sativa L.) tissues was evaluat

188 hways and biological activities of PEGylated BP nanosheets in cancer cells are revealed for the first

189 Bullous pemphigoid (BP) is an autoimmune bullous disease of the skin charact

190 a histologic hallmark of bullous pemphigoid (BP), a subepidermal autoimmune blistering disease charac

191 The outcome of bullous pemphigoid (BP), the most frequent autoimmune skin-blistering diseas

192 Liquid-crystal blue phases (BPs) are highly ordered at two levels.

193 tability of the surface of black phosphorus (BP) under atmospheric conditions is a significant constr

194 of mechanically exfoliated black phosphorus (BP).

195 was measured in paired SP and blood plasma (BP) at baseline and after 1, 2, 4, 6, 8, 12, 18, and 24

196 The predominant BP nsEP parameters that induce BPC consist of a positive

197 ndomized controlled trial examining prenatal BP.

198 c IH on breathing along with blood pressure (BP) and assessed whether the autonomic responses are nor

199 Secular trends in blood pressure (BP) and body mass index (BMI) during childhood and adole

200 activity (MSNA), continuous blood pressure (BP) and electrocardiography were measured at baseline, a

201 hether intensive lowering of blood pressure (BP) at the acute phase of intracerebral haemorrhage (ICH

202 a are sparse regarding which blood pressure (BP) components in young adulthood optimally determine ca

203 ide-treated patients achieve blood pressure (BP) control.

204 MHT), defined as nonelevated blood pressure (BP) in the clinic setting and elevated BP assessed by am

205 Blood pressure (BP) is regulated at the central nervous system, renal, a

206 ly unknown whether intensive blood pressure (BP) lowering beyond that recommended would lead to more

207 ed trials of early intensive blood pressure (BP) lowering in patients with ICH (<6 hours) and elevate

208 determine whether aggressive blood pressure (BP) lowering prevents recurrent atrial fibrillation (AF)

209 vices for monitoring central blood pressure (BP) maintain the cuff pressure at a constant level to ac

210 in-1 (ET-1) is implicated in blood pressure (BP) regulation, we hypothesized that E2's effects on MAP

211 ing metabolic rate (RMR) and blood pressure (BP) through its actions in the arcuate nucleus (ARC).

212 instead of or in addition to blood pressure (BP) to guide antihypertensive treatment is an active are

213 Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) eve

214 Blood pressure (BP) was directly measured by the arterial catheter and f

215 dated scales, and ambulatory blood pressure (BP) was measured every 15 minutes during the working day

216 evidence that self-measured blood pressure (BP) without other augmentation is superior to office-bas

217 renal tubule is critical for blood pressure (BP), acid-base, and potassium homeostasis.

218 In adults, high blood pressure (BP), adverse serum lipids, and smoking associate with co

219 hypertension based on clinic blood pressure (BP), it is unclear who should be screened for masked hyp

220 ence variants that influence blood pressure (BP).

221 n ADHF events from intensive blood pressure [BP] treatment among the 6 key, prespecified subgroups in

222 antibodies against the transmembrane protein BP antigen 2 (BP180, type XVII collagen) has previously

223 ne synthase) treatment significantly reduced BPs of hAS(+/-) mice on HS.

224 Although regenerated BPs were reduced in numbers, BP dendritic spreads, dendr

225 nerated retinas, suggesting that regenerated BPs recover accurate input pathways from surviving cone

226 ed from both postmortem human brain regions (BP case/control: 45/50) and peripheral blood mononuclear

227 All studies reported BP at baseline and the end of the trial.

228 Our approach developed a scalable BP genetic database (BP_GD), including BP related genes,

229 counselling) leads to clinically significant BP reduction which persists for at least 12 months.

230 ArchT photoactivation produced similar BP changes in CaMKII-ArchT-treated rats.

231 ribution in CVD risk for people with similar BP levels, and the use of CVD risk for guiding antihyper

232 ized pigs subjected to a transient or stable BP increase induced by adrenaline administration.

233 intensive BP-lowering treatment and standard BP-lowering treatment (OR: 0.99; 95% CI: 0.82 to 1.20, p

234 to either intensive BP-lowering or standard BP-lowering treatment protocols.

235 BP <120 mm Hg) and 4078 assigned to standard BP lowering (target SBP <140 mm Hg).

236 stolic BP <120 mm Hg) compared with standard BP lowering (target systolic BP <140 mm Hg) resulted in

237 95% CI: 0.43 to 0.99) compared with standard BP lowering.

238 assigned to the intensive (versus standard) BP lowering were 66% more likely to regress/improve thei

239 th three of the four possible stereoisomeric BP-N (2) -dG adducts, which gives insights how Rev1 achi

240 ecently showed an association between strict BP control and lower mortality risk during two decades o

241 2) systolic BP lowering to a target of <130 mm Hg may reduce the ris

242 significant difference in achieved systolic BP, AngII-treated APA-KO mice developed a significant ri

243 ith a 1.04-mm Hg decrement in adult systolic BP (95% confidence interval (CI): -2.14, 0.06) and a 0.6

244 KD per 1-SD decrease in mean asleep systolic BP, independent of changes in mean clinic BP or awake am

245 lack race, and 3 levels of baseline systolic BP (</=132 versus >132 to <145 versus >/=145 mm Hg).

246 e interval, 0.663-0.744) for clinic systolic BP and diastolic BP.

247 ive patients, intensive BP control (systolic BP <140 mm Hg) decreased MACE, including cardiovascular

248 6.8/-3.5 mm Hg, respectively, Delta systolic BP P=3x10(-4), Delta diastolic BP P=5x10(-5)).

249 othiazide versus noncarriers (Delta systolic BP/Delta diastolic BP: -12.3/-8.2 versus -6.8/-3.5 mm Hg

250 ts with ICH (<6 hours) and elevated systolic BP (150-220 mm Hg).

251 tiles from the 81.6th to 99.9th for systolic BP and from the 92.9th to 98.9th for diastolic BP in the

252 years, body mass index, and higher systolic BP.

253 Tmem27(Y/-) kidneys had the highest systolic BP and were the only group to exhibit glomerular mesangi

254 dest but significant improvement in systolic BP in randomized controlled trials of self-measured BP v

255 target <140 mm Hg) with intensive (systolic BP target <120 mm Hg) BP treatment and data from the Nat

256 ) had 3.6, 3.5, and 3.6 mm Hg lower systolic BP in low, middle, and high genetic risk groups, respect

257 FBX had a modest systolic BP-lowering effect in T1D patients (112 +/- 10 to 109 +/

258 ure between ages 6 and 24 years) of systolic BP, total-cholesterol, and smoking associated inversely

259 ere not consistent, for both sexes, systolic BP z-score was stable from 1999, decreased slightly from

260 lts of 2 trials comparing standard (systolic BP target <140 mm Hg) with intensive (systolic BP target

261 itus, intensive BP lowering (target systolic BP <120 mm Hg) compared with standard BP lowering (targe

262 d with standard BP lowering (target systolic BP <140 mm Hg) resulted in lower rates of developing new

263 body overhydration, correlated with systolic BP (r=0.33, P=0.002).

264 lable for association analysis with systolic BP or diastolic BP or pulse pressure.

265 The computational biology approach and the BP database developed in this study could contribute to

266 ignals recorded with cuff electrodes and the BP waves recorded with carotid catheters were ensemble a

267 In this review, we discuss the BP measurement techniques used in major observational st

268 mic force microscopy to obtain images of the BP surface and hexagonal supramolecular networks of trim

269 old nanoparticles that were sputtered on the BP through surface functionalization.

270 solution structures of yeast Rev1 with three BP-N (2)-dG adducts, namely the 10S (+)-trans-BP-N (2)-d

271 bare BPs, BPs with TiL4 modification (TiL4 @BPs) can efficiently escape from macrophages uptake, and

272 ophenotypes can facilitate new approaches to BP prediction, diagnosis, and prevention.

273 activated eosinophils directly contribute to BP blister formation in the presence of BP autoantibodie

274 rmoxia, but their activation is important to BP stability during hypoxia or anesthesia and contribute

275 P-N (2)-dG adducts, namely the 10S (+)-trans-BP-N (2)-dG, 10R (+)-cis-BP-N (2)-dG, and 10S ( - )-cis-

276 rther demonstrate that such a widely tunable BP photodetector exhibits a peak extrinsic photo-respons

277 and CVD events regardless of the underlying BP genetic risk.

278 previously randomized to strict versus usual BP control.

279 = 2.05 x 10-6; Bonferroni-corrected P value [BP] = 1.3 x 10-3) and LOAD (P = 6.22 x 10-6; BP = 4.1 x

280 , sex-, and region-specific z-scores for WC, BP, HDL-C, and TGs.

281 er alternatively spliced regions with weaker BPs.

282 canagliflozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers

283 We sought to assess whether BP outcome was associated with different CXCL10 levels a

284 g08035323 (TAF1B-YWHAQ) influences BP, while BP influences methylation at cg00533891 (ZMIZ1), cg00574

285 ho completed an fMRI attention task: 24 with BP, 29 at risk based on a first-degree relative with BP,

286 lifestyle score was strongly associated with BP (P<10(-320)) for systolic and diastolic BP and CVD ev

287 her previously reported loci associated with BP in studies of European, African, and Asian ancestry g

288 We report 4 novel loci associated with BP regulation, and 1 independent variant at an establish

289 tify novel molecular markers associated with BP response to TD.

290 l data on using CVD risk in conjunction with BP to guide antihypertensive treatment, the broad distri

291 Of 117 patients with BP (69 women and 48 men), anti-BP180 NC16A serum IgE was

292 evels with disease activity in patients with BP supports the notion that anti-BP180 IgE is of pathoge

293 Sixty-five patients with BP underwent an enzyme-linked immunosorbent assay for Ig

294 BP180 (NC16A); 52 consecutive patients with BP underwent clinical evaluation with the Bullous Pemphi

295 Activity Index (BPDAI); and 36 patients with BP without anti-BP180 NC16A IgG reactivity underwent eva

296 of inflammatory biomarkers in patients with BP, such as CXCL10, favor neutrophil- and monocyte-assoc

297 se of omalizumab in individual patients with BP.

298 and the clinical phenotype of patients with BP.

299 t risk based on a first-degree relative with BP, and 53 healthy, low-risk individuals.

300 yr BP for unknown reasons.